Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
PET
0.019
171.4%
STP
0.265
-44.2%
CKA
0.073
69.8%
VBS
0.11
-37.1%
A1G
0.52
65.1%
IPB
0.006
-33.3%
APC
0.015
50%
NAE
0.002
-33.3%
AYT
0.006
50%
SFG
0.002
-33.3%
ERA
0.003
50%
OVT
0.005
-28.6%
RMY
0.045
45.2%
VUL
4.41
-27.5%
TCG
0.75
38.9%
IMI
0.011
-26.7%
QFE
0.081
37.3%
CTN
0.003
-25%
PNN
0.12
36.4%
MAY
0.009
-25%
DAL
0.054
35%
RKB
0.003
-25%
DMG
0.008
33.3%
NFM
0.016
-23.8%
FBR
0.004
33.3%
EPI
1.005
-23.3%
MRQ
0.004
33.3%
IBX
0.02
-23.1%
BDG
0.08
29%
RML
0.053
-22.1%
MGA
0.081
28.6%
AUR
0.018
-21.7%
NES
0.009
28.6%
LMG
0.023
-20.7%
GR8
0.205
28.1%
AKN
0.004
-20%
EDU
0.77
27.3%
FCT
0.008
-20%
PKY
0.019
26.7%
GLL
0.008
-20%
